|1.||Grant, Steven: 25 articles (05/2014 - 12/2003)|
|2.||Richon, Victoria M: 24 articles (07/2015 - 05/2002)|
|3.||Marks, Paul A: 23 articles (04/2012 - 05/2002)|
|4.||Dent, Paul: 18 articles (05/2014 - 12/2003)|
|5.||Espinoza-Delgado, Igor: 16 articles (10/2015 - 04/2009)|
|6.||Li, Yongqing: 12 articles (04/2015 - 11/2009)|
|7.||Liu, Baoling: 12 articles (04/2015 - 11/2009)|
|8.||Alam, Hasan B: 12 articles (04/2015 - 11/2009)|
|9.||Dai, Yun: 10 articles (06/2013 - 12/2003)|
|10.||Johnstone, Ricky W: 9 articles (11/2015 - 07/2004)|
01/01/2009 - "Suberoylanilide hydroxamic acid (SAHA) is effective against many cancer cells and functions by up-regulating an endogenous inhibitor of Trx. "
02/01/2013 - "In this study, we evaluated the safety, pharmacokinetics, and efficacy of two dosing regimens of vorinostat, an oral HDACi, in patients with GI tumors. "
01/01/2015 - "However, vorinostat-NPs showed improved antitumor activity against HuCC-T1 cancer cell-bearing mice compared to vorinostat, whereas empty nanoparticles had no effect on tumor growth. "
08/01/2014 - "Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells."
09/15/2000 - "Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar compounds that induce growth arrest in transformed cells and show promise for the treatment of cancer. "
|2.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
05/15/2015 - "Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors."
01/01/2012 - "This review introduces the background and mechanism of action of vorinostat and describes the results of clinical trials using vorinostat, both as a single agent and in combination with other anticancer agents, against cutaneous T-cell lymphoma and other malignancies."
10/14/2010 - "Suberoylanilide hydroxamic acid (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi and other agents have been actively tested in many clinical trials. "
05/01/2008 - "A large number of these agents that have different chemical structures and can target multiple HDACs are being testing in clinical trials and vorinostat is now an approved drug for the treatment of cutaneous T-cell lymphoma. "
06/01/2007 - "A well-known HDACi, suberoylanilide hydroxamic acid, has been recently approved for the treatment of cutaneous T cell lymphoma, and a number of HDACi are in clinical trials as anticancer drugs. "
10/14/2010 - "A gene expression analysis performed in a phase 1 trial of vorinostat in leukemia indicated that overexpression of genes involved in antioxidant defense was associated with clinical resistance. "
01/01/2015 - "Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells."
08/01/2014 - "ZYJ-34c strongly inhibited the proliferation of leukemia cells compared with suberoylanilide hydroxamic acid. "
06/01/2013 - "Leukemia cell lines carrying FLT3-ITD were also sensitive to the MK-8776/vorinostat regimen. "
04/01/2013 - "No differences in percentage S-phase cells or multidrug resistance transporter (MDR1 or BCRP) expression or function were observed in vivo in leukemia blasts upon vorinostat treatment. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/01/2009 - "Future studies of vorinostat in acute myeloid leukemia should focus on combinations with other drugs with which it might interact pharmacodynamically. "
10/01/2009 - "A phase 2 study of vorinostat in acute myeloid leukemia."
05/01/2014 - "Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases."
10/01/2009 - "Vorinostat monotherapy demonstrated minimal activity in this group of patients with acute myeloid leukemia. "
06/01/2013 - "Finally, the MK-8776/vorinostat regimen was active in primary acute myelogenous leukemia (AML) blasts, particularly against the CD34(+)/CD38(-)/CD123(+) population enriched for leukemia-initiating cells. "
|5.||Breast Neoplasms (Breast Cancer)
11/01/2011 - "This variant is common in Asians but rare in Caucasians, and we studied its impact on vorinostat pharmacokinetics and pharmacodynamics in a clinical study in Asian patients with metastatic breast cancer. "
11/01/2008 - "The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. "
01/01/2016 - "Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals."
07/01/2015 - "Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer."
07/15/2013 - "This demonstration of biologic activity supports investigation of vorinostat in combination with other agents for the management of breast cancer."
|1.||Histone Deacetylase Inhibitors
|2.||vorinostat (suberoylanilide hydroxamic acid)
|3.||trichostatin A (A 300)
|4.||Histone Deacetylases (Histone Deacetylase)
|6.||Valproic Acid (Valproate, Semisodium)
|8.||Proteasome Endopeptidase Complex (Proteasome)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Molecular Targeted Therapy